Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):267-72. doi: 10.1177/1074248411408313.

The role of comorbidities in cardioprotection.

Author information

  • 1Center for Molecular Medicine, NHLBI, NIH, Bethesda, MD, USA.

Abstract

Cardioprotective strategies such as pre- and postconditioning result in a robust reduction in infarct size in young, healthy male animals. However, there are data suggesting that the protection is diminished in animals with comorbidities such as hypertension, hypercholesterolemia, and diabetes. It is important to understand at a mechanistic level the reasons for these differences. The effects of sex and diseases need to be considered in design of cardioprotective interventions in animal studies and clinical trials.

PMID:
21821527
[PubMed - indexed for MEDLINE]
PMCID:
PMC3398382
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk